Related Experiment Video
Updated: Jun 1, 2026
10:19
Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
Published on: August 22, 2014
Noradrenaline and Parkinson's disease
Claire Delaville1, Philippe De Deurwaerdère, Abdelhamid Benazzouz
1UMR 5293, Institut des Maladies Neurodégénératives, Université de Bordeaux Bordeaux, France.
Frontiers in Systems Neuroscience
|June 8, 2011
Summary
Parkinson's disease involves dopamine neuron loss, but noradrenaline neuron loss also impacts motor and non-motor symptoms. Targeting noradrenaline pathways may improve Parkinson's treatment.
Area of Science:
- Neuroscience
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) involves dopamine neuron degeneration, causing motor deficits.
- Current models struggle to replicate PD's full spectrum of motor and non-motor symptoms.
- Noradrenaline (NA) neuron loss in the locus coeruleus is increasingly implicated in PD.
Purpose of the Study:
- To review evidence on noradrenaline's role in Parkinson's pathophysiology.
- To analyze the impact of NA depletion on motor and non-motor PD symptoms.
- To evaluate the therapeutic potential of targeting noradrenergic systems in PD.
Main Methods:
- Analysis of existing literature on animal models of parkinsonism.
- Review of clinical data from parkinsonian patients.
- Examination of studies using selective alpha-receptor agonists and antagonists.
Main Results:
- Noradrenaline depletion, alone or with dopamine loss, causes both motor and non-motor PD symptoms.
- Alpha-2 receptors are involved in motor control.
- Alpha-2 receptor antagonists show potential in improving PD motor symptoms and L-DOPA-induced dyskinesia.
Conclusions:
- Noradrenaline neuron loss significantly impacts all Parkinson's disease symptoms.
- Combining noradrenergic agents with dopaminergic medication could offer enhanced PD treatment benefits.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...